Tepotinib
from OncoPharm Hosted by John Bossaer
In light of teptinib's recent FDA-approval for exon-14 skipping MET altered metastatic NSLCC, we compare tepotinib to its predecessor in this space - capmatinib.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 15 minutes long.
When was this OncoPharm episode published?
This episode was published on February 4, 2021.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.